« Return to News | Awards & Advancement

Adventrx names Vetticaden as chief medical officer

Monday, August 20, 2012 04:01 PM

Adventrx Pharmaceuticals, a biopharmaceutical company based in San Diego, has appointed Santosh J. Vetticaden, M.D., Ph.D., as chief medical officer and senior vice president.

Vetticaden has more than 25 years of experience in drug development and medicine, spanning a variety of therapeutic areas, including anticoagulation, hemophilia, anti-infectives and rheumatology/inflammation. He has directed and managed the clinical development of both large and small molecules, from protocol design to execution of multi-center, global clinical trials.

Before joining Adventrx, Vetticaden held several senior level positions leading drug development across phase I through phase IV trials at biotech and large pharmaceutical companies. Most recently, he served as senior vice president and chief medical and development officer at Cubist Pharmaceuticals, where his tenure was highlighted by successful phase II trials and advancing multiple drugs into phase III. Prior to that, he held senior positions at Maxygen; Scios, a subsidiary of Johnson & Johnson; Aventis Pharmaceuticals (Sanofi); and the Whitehall-Robins Healthcare division of American Home Products (Pfizer).

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.